Compile Data Set for Download or QSAR
Report error Found 558 Enz. Inhib. hit(s) with all data for entry = 12729
TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723955(US20250064789, Compound 534)
Affinity DataIC50: 1.14E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723567(US20250064789, Compound 141)
Affinity DataIC50: 1.16E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723772(US20250064789, Compound 351)
Affinity DataIC50: 1.16E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723979(US20250064789, Compound 558)
Affinity DataIC50: 1.18E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723568(US20250064789, Compound 142)
Affinity DataIC50: 1.21E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723896(US20250064789, Compound 475)
Affinity DataIC50: 1.22E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723875(US20250064789, Compound 454)
Affinity DataIC50: 1.30E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723894(US20250064789, Compound 473)
Affinity DataIC50: 1.31E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723890(US20250064789, Compound 469)
Affinity DataIC50: 1.43E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723687(US20250064789, Compound 263)
Affinity DataIC50: 1.56E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723898(US20250064789, Compound 477)
Affinity DataIC50: 1.86E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723887(US20250064789, Compound 466)
Affinity DataIC50: 1.95E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723891(US20250064789, Compound 470)
Affinity DataIC50: 2.03E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723855(US20250064789, Compound 434)
Affinity DataIC50: 2.05E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723986(US20250064789, Compound 565)
Affinity DataIC50: 2.07E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723901(US20250064789, Compound 480)
Affinity DataIC50: 2.23E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723900(US20250064789, Compound 479)
Affinity DataIC50: 2.24E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723916(US20250064789, Compound 495)
Affinity DataIC50: 2.27E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723724(US20250064789, Compound 300)
Affinity DataIC50: 2.43E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723471(US20250064789, Compound 41)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723615(US20250064789, Compound 189)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723688(US20250064789, Compound 264)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723694(US20250064789, Compound 270)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723696(US20250064789, Compound 272)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723769(US20250064789, Compound 346)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723770(US20250064789, Compound 347)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723773(US20250064789, Compound 352)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723776(US20250064789, Compound 355)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723790(US20250064789, Compound 369)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723980(US20250064789, Compound 559)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723983(US20250064789, Compound 562)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723984(US20250064789, Compound 563)
Affinity DataIC50: 2.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723886(US20250064789, Compound 465)
Affinity DataIC50: 2.55E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723888(US20250064789, Compound 467)
Affinity DataIC50: 3.37E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723885(US20250064789, Compound 464)
Affinity DataIC50: 3.50E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723899(US20250064789, Compound 478)
Affinity DataIC50: 3.62E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723593(US20250064789, Compound 167)
Affinity DataIC50: 3.81E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723462(US20250064789, Compound 28)
Affinity DataIC50: 5.00E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723463(US20250064789, Compound 29)
Affinity DataIC50: 5.00E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723464(US20250064789, Compound 30)
Affinity DataIC50: 5.00E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723465(US20250064789, Compound 31)
Affinity DataIC50: 5.00E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723466(US20250064789, Compound 32)
Affinity DataIC50: 5.00E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723467(US20250064789, Compound 34)
Affinity DataIC50: 5.00E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723470(US20250064789, Compound 39)
Affinity DataIC50: 5.00E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723669(US20250064789, Compound 245)
Affinity DataIC50: 5.00E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723758(US20250064789, Compound 334)
Affinity DataIC50: 5.00E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723911(US20250064789, Compound 490)
Affinity DataIC50: 5.21E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723508(US20250064789, Compound 82)
Affinity DataIC50: 5.80E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723762(US20250064789, Compound 339)
Affinity DataIC50: 6.13E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Westvac Biopharma Co.

US Patent
LigandPNGBDBM723509(US20250064789, Compound 83)
Affinity DataIC50: 6.70E+3nMAssay Description:The recombinant SARS-CoV-2 Mpro (with a final concentration of 750 nM) was mixed with a series of dilutions for each compound in 25 μL assay buffer (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/29/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 558 total ) | Next | Last >>
Jump to: